Skip to main content

Table 3 RBC-TI ≥26 weeks and cytogenetic response by age group in patients treated with lenalidomide

From: Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)

Response

<65 years

(n = 97)a

≥65 to <75 years

(n = 98)

≥75 years

(n = 91)

RBC-TI ≥26 weeks, n (%)

54 (55.7)

53 (54.1)

41 (45.1)

Median time to RBC-TI ≥26 weeks, weeks (range)b

2.48 (1.49–NE)

2.48 (1.36–NE)

7.80 (2.15–NE)

Median duration of RBC-TI ≥26 weeks, years (range)b

4.60 (2.31–NE)

3.19 (1.74–NE)

2.19 (1.20–NE)

Cytogenetic response, n/N (%)

 Major + minor

32/71 (45.1)

38/58 (65.5)

33/52 (63.5)

  1. NE not estimable, RBC-TI red blood cell transfusion independence
  2. p = 0.022 vs. ≥65 to <75 years; p = 0.047 vs. ≥75 years
  3. aOne patient in the <65 years group was later diagnosed with acute myeloid leukemia, which had been present at the start of the study
  4. bResponding patients only